NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26) - PubMed (original) (raw)

. 2009 Apr 17;381(4):491-5.

doi: 10.1016/j.bbrc.2009.02.069. Epub 2009 Feb 20.

Affiliations

• PMID: 19233143
• DOI: 10.1016/j.bbrc.2009.02.069

NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26)

Mina Song et al. Biochem Biophys Res Commun. 2009.

Abstract

Protein phosphorylation plays critical roles in many regulatory mechanisms controlling cell activities and thus involved in various diseases. The cellular equilibrium of phosphorylation is regulated through the actions of protein kinases and phosphatases. Therefore, these regulatory proteins have emerged as promising targets for drug development. In this study, we screened protein tyrosine phosphatases (PTPs) by in vitro phosphatase assays to identify PTPs that are inhibited by 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877), a potent inhibitor of SHP-1 and SHP-2 PTPs. Phosphatase activity of dual-specificity protein phosphatase 26 (DUSP26) was decreased by the inhibitor in a dose-dependent manner. Kinetic studies with NSC-87877 and DUSP26 revealed a competitive inhibition. NSC-87877 effectively inhibited DUSP26-mediated dephosphorylation of p38, a member of mitogen-activated protein kinase (MAPK) family. Since DUSP26 is involved in survival of anaplastic thyroid cancer (ATC) cells, NSC-87877 could be a therapeutic reagent for treating ATC.

PubMed Disclaimer

Similar articles

• NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
  Shi Y, Ma IT, Patel RH, Shang X, Chen Z, Zhao Y, Cheng J, Fan Y, Rojas Y, Barbieri E, Chen Z, Yu Y, Jin J, Kim ES, Shohet JM, Vasudevan SA, Yang J. Shi Y, et al. Cell Death Dis. 2015 Aug 6;6(8):e1841. doi: 10.1038/cddis.2015.207. Cell Death Dis. 2015. PMID: 26247726 Free PMC article.
• PTP inhibitor IV protects JNK kinase activity by inhibiting dual-specificity phosphatase 14 (DUSP14).
  Park JE, Park BC, Song M, Park SG, Lee DH, Park SY, Kim JH, Cho S. Park JE, et al. Biochem Biophys Res Commun. 2009 Oct 2;387(4):795-9. doi: 10.1016/j.bbrc.2009.07.127. Epub 2009 Jul 29. Biochem Biophys Res Commun. 2009. PMID: 19646420
• Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?
  Dempke WCM, Uciechowski P, Fenchel K, Chevassut T. Dempke WCM, et al. Oncology. 2018;95(5):257-269. doi: 10.1159/000490106. Epub 2018 Jun 20. Oncology. 2018. PMID: 29925063 Review.
• A Review of DUSP26: Structure, Regulation and Relevance in Human Disease.
  Thompson EM, Stoker AW. Thompson EM, et al. Int J Mol Sci. 2021 Jan 14;22(2):776. doi: 10.3390/ijms22020776. Int J Mol Sci. 2021. PMID: 33466673 Free PMC article. Review.

Cited by

• N-Acetyl-seryl-aspartyl-lysyl-proline inhibits ET-1-induced collagen production by preserving Src homology 2-containing protein tyrosine phosphatase-2 activity in cardiac fibroblasts.
  Peng H, Carretero OA, Peterson EL, Yang XP, Santra K, Rhaleb NE. Peng H, et al. Pflugers Arch. 2012 Oct;464(4):415-23. doi: 10.1007/s00424-012-1150-7. Epub 2012 Sep 12. Pflugers Arch. 2012. PMID: 22968858 Free PMC article.
• Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells.
  Chu LY, Ramakrishnan DP, Silverstein RL. Chu LY, et al. Blood. 2013 Sep 5;122(10):1822-32. doi: 10.1182/blood-2013-01-482315. Epub 2013 Jul 29. Blood. 2013. PMID: 23896411 Free PMC article.
• The Discovery of Potent SHP2 Inhibitors with Anti-Proliferative Activity in Breast Cancer Cell Lines.
  Ghemrawi R, Khair M, Hasan S, Aldulaymi R, AlNeyadi SS, Atatreh N, Ghattas MA. Ghemrawi R, et al. Int J Mol Sci. 2022 Apr 18;23(8):4468. doi: 10.3390/ijms23084468. Int J Mol Sci. 2022. PMID: 35457286 Free PMC article.
• Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI.
  Bohländer F, Riehl D, Weißmüller S, Gutscher M, Schüttrumpf J, Faust S. Bohländer F, et al. Front Immunol. 2021 Jun 10;12:700429. doi: 10.3389/fimmu.2021.700429. eCollection 2021. Front Immunol. 2021. PMID: 34177967 Free PMC article.
• Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
  Song Z, Wang M, Ge Y, Chen XP, Xu Z, Sun Y, Xiong XF. Song Z, et al. Acta Pharm Sin B. 2021 Jan;11(1):13-29. doi: 10.1016/j.apsb.2020.07.010. Epub 2020 Jul 26. Acta Pharm Sin B. 2021. PMID: 33532178 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program